Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Related News

MASTERS SPECIALITY PHARMA ANNOUNCES ITS APPOINTMENT AS AMGEN’S EXCLUSIVE DISTRIBUTOR

Masters Speciality Pharma | January 18, 2017

news image

Masters Speciality Pharma is pleased to announce its appointment as Amgen (Europe) GmbH’s exclusive supplier of XGEVA® (denosumab), Prolia® (denosumab) and Neupogen® (filgrastim), to government bodies, hospitals and Health Care Professionals in Azerbaijan, Costa Rica, Pakistan, Panama, Uruguay and Senegal....

Read More

WHO BOASTS THE BIGGEST OVERSEAS CASH COFFERS? AMGEN AND GILEAD, TO NAME A COUPLE

FiercePharma | May 01, 2017

news image

At January’s JPMorgan Healthcare Conference, Amgen CEO Robert Bradway proclaimed that his company would be “a clear beneficiary” of any corporate tax reform U.S. President Donald Trump could enact....

Read More

NICE NOD FOR AMGEN’S RARE LEUKAEMIA DRUG

Pharma times | May 03, 2017

news image

The Institute has published final draft guidance recommending Blincyto (blinatumomab) as an option for treating adults with Philadelphia-chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL), on the basis of the discount agreed in the patient access scheme....

Read More

NOVARTIS TO GLOBALLY CO-COMMERCIALISE AMGEN’S MIGRAINE DRUG

European Pharmaceutical Review | April 27, 2017

news image

Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine....

Read More
news image

MASTERS SPECIALITY PHARMA ANNOUNCES ITS APPOINTMENT AS AMGEN’S EXCLUSIVE DISTRIBUTOR

Masters Speciality Pharma | January 18, 2017

Masters Speciality Pharma is pleased to announce its appointment as Amgen (Europe) GmbH’s exclusive supplier of XGEVA® (denosumab), Prolia® (denosumab) and Neupogen® (filgrastim), to government bodies, hospitals and Health Care Professionals in Azerbaijan, Costa Rica, Pakistan, Panama, Uruguay and Senegal....

Read More
news image

WHO BOASTS THE BIGGEST OVERSEAS CASH COFFERS? AMGEN AND GILEAD, TO NAME A COUPLE

FiercePharma | May 01, 2017

At January’s JPMorgan Healthcare Conference, Amgen CEO Robert Bradway proclaimed that his company would be “a clear beneficiary” of any corporate tax reform U.S. President Donald Trump could enact....

Read More
news image

NICE NOD FOR AMGEN’S RARE LEUKAEMIA DRUG

Pharma times | May 03, 2017

The Institute has published final draft guidance recommending Blincyto (blinatumomab) as an option for treating adults with Philadelphia-chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL), on the basis of the discount agreed in the patient access scheme....

Read More
news image

NOVARTIS TO GLOBALLY CO-COMMERCIALISE AMGEN’S MIGRAINE DRUG

European Pharmaceutical Review | April 27, 2017

Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine....

Read More